{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:16:25Z","timestamp":1761488185792},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1038\/ja.2006.43","type":"journal-article","created":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T11:30:21Z","timestamp":1232364621000},"page":"303-308","source":"Crossref","is-referenced-by-count":3,"title":["Enhanced Activity of Rifalazil in Combination with Levofloxacin, Linezolid, or Mupirocin against Staphylococcus aureus In Vitro"],"prefix":"10.1038","volume":"59","author":[{"given":"Marcia S","family":"Osburne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher K","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFja200643_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543784.12.2.255","volume":"12","author":"DM Rothstein","year":"2003","unstructured":"Rothstein DM, Hartman AD, Cynamon M, Eisenstein BI . Development potential of Rifalazil. Expert Opin Investig Drugs 12: 1\u201317 ( 2003)","journal-title":"Expert Opin Investig Drugs"},{"key":"BFja200643_CR2","first-page":"537","volume-title":"Antibiotics in Laboratory Medicine","author":"DJ Krogstad","year":"1986","unstructured":"Krogstad DJ, Moellering RC . Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 2nd Edition. Ed., Lorian V . . The Williams & Wilkins, Baltimore, MD, pp. 537\u2013595 (1986)"},{"key":"BFja200643_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ja.2006.11","volume":"59","author":"MS Osburne","year":"2006","unstructured":"Osburne MS, Rothstein DM, Farquhar R, Murphy CK . In Vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus. J Antibiot 59: 80\u201385 ( 2006)","journal-title":"J Antibiot"},{"key":"BFja200643_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jac\/15.5.523","volume":"15","author":"MW Casewell","year":"1985","unstructured":"Casewell MW, Hill RL . In vitro activity of mupirocin (\u201cpseudomonic acid\u201d) against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 15: 523\u2013531 ( 1985)","journal-title":"J Antimicrob Chemother"},{"key":"BFja200643_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1128\/AAC.47.1.418-420.2003","volume":"47","author":"P Grohs","year":"2003","unstructured":"Grohs P, Kitzis MD, Gurmann L . In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 47: 418\u2013420 ( 2003)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jac\/dkg160","volume":"51","author":"C Jacqueline","year":"2003","unstructured":"Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Donnio PY, Bugnon D, Potel G . In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistatnt Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 51: 857\u2013864 ( 2003)","journal-title":"J Antimicrob Chemother"},{"key":"BFja200643_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1128\/AAC.40.4.839","volume":"40","author":"GE Zurenko","year":"1996","unstructured":"Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SH . In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40: 839\u2013845 ( 1996)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1128\/AAC.44.2.255-260.2000","volume":"44","author":"J Gisby","year":"2000","unstructured":"Gisby J, Bryant J . Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 44: 255\u2013260 ( 2000)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1128\/AAC.27.4.495","volume":"27","author":"RR Sutherland","year":"1985","unstructured":"Sutherland RR, Boon J, Friffin KE, Masters PJ, Slocombe B, White AR . Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 27: 495\u2013498 ( 1985)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1086\/341025","volume":"35","author":"MD Kalmeijer","year":"2002","unstructured":"Kalmeijer MD, Coertjens H, van Nieuwland-Bolland PM, Bogaers-Hofman D, de Baere GA, Stuurman A, van Belkum A, Kluytmans JA . Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 35: 353\u2013358 ( 2002)","journal-title":"Clin Infect Dis"},{"key":"BFja200643_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijantimicag.2003.09.030","volume":"23","author":"L Alou","year":"2004","unstructured":"Alou L, Cafini F, Sevillano D, Unzueta I, Prieto J . In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against Staphylococci including those resistant to methicillin. International J Antimicrob Agents 23: 513\u2013516 ( 2004)","journal-title":"International J Antimicrob Agents"},{"key":"BFja200643_CR12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/AAC.41.6.1293","volume":"41","author":"DD Bahl","year":"1997","unstructured":"Bahl DD, Miller A, Leviton I, Gialanella P, Wolin MJ, Liu W, Perkins R, Miller MH . In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and non-growing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 41: 1293\u20131297 ( 1997)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR13","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1128\/AAC.38.12.2702","volume":"38","author":"SL Kang","year":"1994","unstructured":"Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM . Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 38: 2702\u20132709 ( 1994)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1128\/AAC.38.5.1118","volume":"Chemother","author":"K Fujii","year":"1994","unstructured":"Fujii K, Tsuji A, Miyazaki S, Yamaguchi K, Goto S . In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob Agents Chemother: 1118\u20131122 ( 1994)","journal-title":"Antimicrob Agents"},{"key":"BFja200643_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/infdis\/140.4.629","volume":"140","author":"DW Norden","year":"1979","unstructured":"Norden DW, Wentzel H, Keleti E . Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis 140: 629\u2013633 ( 1979)","journal-title":"J Infect Dis"},{"key":"BFja200643_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/AAC.18.5.699","volume":"18","author":"RD Pearson","year":"1980","unstructured":"Pearson RD, Seigbigel RT, Davis HT, Chapman S . Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 18: 699\u2013708 ( 1980)","journal-title":"Antimicrob Agents Chemother"},{"key":"BFja200643_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1128\/AAC.40.3.677","volume":"40","author":"DM Cappelletty","year":"1996","unstructured":"Cappelletty DM, Rybak MJ . Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 40: 677\u2013683 ( 1996)","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja200643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja200643","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja200643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:11:38Z","timestamp":1684429898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja200643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["BFja200643"],"URL":"https:\/\/doi.org\/10.1038\/ja.2006.43","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}